Literature DB >> 8144940

Recombinant and native zymogen forms of human complement factor D.

Y Yamauchi1, J W Stevens, K J Macon, J E Volanakis.   

Abstract

We have expressed a full-length cDNA clone encoding human factor D by using a baculovirus expression system. The purified recombinant protein reacted with Ab against native factor D, but was hemolytically inactive and slightly larger than factor D. These results suggested that the recombinant protein was the elusive zymogen of factor D. Amino acid sequencing demonstrated that the recombinant factor D consisted of two proenzyme forms with respective activation peptides, AAPPRGR and APPRGR. Catalytic amounts of trypsin converted recombinant profactor D to its enzymatically active form, exhibiting SDS-PAGE mobility and specific hemolytic activity similar to those of native factor D. About 90% of trypsin-activated recombinant profactor D had the same NH2-terminus as factor D. Human thrombin, kallikrein, and plasmin could also activate recombinant profactor D, but relatively high concentrations of these enzymes were required and the specific hemolytic activity of the "activated" profactor D was about one-third that of native factor D. Trypsin-activatable profactor D was also purified from the urine of a patient with Fanconi's syndrome. This native profactor D represented less than 1.0% of the total antigenic factor D in the patient's urine and had a Gly-Arg dipeptide as the activation peptide. Apparently, urine profactor D was produced by cleavage of pre-profactor D at Arg-(-3) by a serine protease with trypsin-like specificity, which probably is different from the putative leader peptidase that produces the recombinant profactor D. Urine profactor D was inhibited by diisopropyl fluorophosphate although the recombinant proenzyme was resistant to this inhibitor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144940

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis.

Authors:  Nirmal K Banda; Minoru Takahashi; Brandt Levitt; Magdalena Glogowska; Jessica Nicholas; Kazue Takahashi; Gregory L Stahl; Teizo Fujita; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

2.  Roles of adipocytes and fibroblasts in activation of the alternative pathway of complement in inflammatory arthritis in mice.

Authors:  William P Arend; Gaurav Mehta; Alexandra H Antonioli; Minoru Takahashi; Kazue Takahashi; Gregory L Stahl; V Michael Holers; Nirmal K Banda
Journal:  J Immunol       Date:  2013-05-06       Impact factor: 5.422

Review 3.  Complement factor D, a novel serine protease.

Authors:  J E Volanakis; S V Narayana
Journal:  Protein Sci       Date:  1996-04       Impact factor: 6.725

Review 4.  Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes.

Authors:  A R Khan; M N James
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

5.  Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement.

Authors:  Nirmal K Banda; Minoru Takahashi; Kazue Takahashi; Gregory L Stahl; Stephanie Hyatt; Magdalena Glogowska; Timothy A Wiles; Yuichi Endo; Teizo Fujita; V Michael Holers; William P Arend
Journal:  Mol Immunol       Date:  2011-09-23       Impact factor: 4.407

6.  Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing.

Authors:  Nirmal K Banda; Sumitra Acharya; Robert I Scheinman; Gaurav Mehta; Marilyne Coulombe; Minoru Takahashi; Hideharu Sekine; Steffen Thiel; Teizo Fujita; V Michael Holers
Journal:  J Immunol       Date:  2016-10-05       Impact factor: 5.422

7.  A family with complement factor D deficiency.

Authors:  D H Biesma; A J Hannema; H van Velzen-Blad; L Mulder; R van Zwieten; I Kluijt; D Roos
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

8.  Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B.

Authors:  S C Williams; J Hinshelwood; S J Perkins; R B Sim
Journal:  Biochem J       Date:  1999-09-15       Impact factor: 3.857

9.  Structural basis of profactor D activation: from a highly flexible zymogen to a novel self-inhibited serine protease, complement factor D.

Authors:  H Jing; K J Macon; D Moore; L J DeLucas; J E Volanakis; S V Narayana
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

10.  Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D.

Authors:  Minoru Takahashi; Yumi Ishida; Daisuke Iwaki; Kazuko Kanno; Toshiyuki Suzuki; Yuichi Endo; Yoshimi Homma; Teizo Fujita
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.